Synthesis: A New Frontier in Neuropharmacology
The convergence of directed evolution, viral gene delivery, and structural biology offers an unprecedented
opportunity to address the core molecular deficits of Autism Spectrum Disorder. By transitioning from the
blunt instrument of systemic pharmacology to the surgical precision of molecular engineering, we can target
the GABAergic system with a level of specificity previously unimaginable.
We have explored how:
1. **Receptor Evolution** can create variants that compensate for low ligand availability or altered
kinetics.
2. **Transporter Engineering** can fine-tune the temporal dynamics of inhibition in the synapse.
3. **Metabolic Modulation** of GABA-T can provide "on-demand" inhibition during states of hyperexcitability.
4. **Viral Vectors** enable the delivery of these evolved tools across the blood-brain barrier to specific
neuronal populations.
The road ahead is paved with challenges, but the potential reward—restoring the symphony of neural synchrony
for millions of individuals—makes it a journey worth taking.
References
[1] Cellot, G., & Cherubini, E. (2014). GABAergic signaling as therapeutic target for autism spectrum
disorders. Frontiers in Pediatrics, 2, 70.
[2] Packer, M. S., & Liu, D. R. (2015). Methods for the directed evolution of proteins. Nature Reviews
Genetics, 16(7), 379-394.
[3] Kristensen, A. S., et al. (2011). SLC6 neurotransmitter transporters: structure, function, and
regulation. Pharmacological Reviews, 63(3), 585-640.
[4] Yocum, A. K., et al. (2019). Mechanism of inactivation of GABA transaminase by the antiepileptic drug
vigabatrin. ACS Chemical Biology, 14(1), 3-8.
[5] Deverman, B. E., et al. (2016). Cre-dependent selection yields AAV variants for widespread gene transfer
to the adult brain. Nature Biotechnology, 34(2), 204-209.
[6] Rubenstein, J. L., & Merzenich, M. M. (2003). Model of autism: increased ratio of excitation/inhibition
in key neural systems. Genes, Brain and Behavior, 2(5), 255-267.
[7] Braat, S., & Kooy, R. F. (2015). The GABAA receptor as a therapeutic target for neurodevelopmental
disorders. Neuron, 86(5), 1103-1116.
[8] Cai, Y., et al. (2019). Targeting astrocyte signaling for the treatment of Autism Spectrum Disorder.
Neuroscience Bulletin, 35(2), 1-13.
Excerpt from: Harnessing Directed Evolution Techniques to Target GABA Receptors, Transporters, and GABA Transaminase in ASD by Peter De Ceuster
© All rights reserved. Do not distribute.